A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Hepatology

• Publication date

  2006-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.JHEP.2006.03.008PMID 16780997
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biological Characterization of Pegylated Interferons

  2005cited by this paper
• Biological characterization of pegylated interferons: a case study.

  2005cited by this paper
• Site of Pegylation and Polyethylene Glycol Molecule Size Attenuate Interferon-α Antiviral and Antiproliferative Activities through the JAK/STAT Signaling Pathway*

  2005influential reference
• Therapeutic Proteins

  2005cited by this paper
• Pegylating IFNs at His-34 Improves the in Vitro Antiviral Activity Through the JAK/STAT Pathway

  2004cited by this paper
• Regulation of gene expression by pegylated IFN-alpha2b and IFN-alpha2b in human peripheral blood mononuclear cells.

  2004cited by this paper
• Regulation of Gene Expression by Pegylated IFN-α2b and IFN-α2b in Human Peripheral Blood Mononuclear Cells

  2004cited by this paper
• Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS).

  2003cited by this paper
• Of JAKs, STATs, blind watchmakers, jeeps and trains

  2003cited by this paper
• NIH Consensus Statement on Management of Hepatitis C: 2002.

  2002cited by this paper
• Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

  2001cited by this paper
• Antiviral Actions of Interferons

  2001cited by this paper
• Structural and Biologic Characterization of Pegylated Recombinant IFN-α2b

  2001cited by this paper
• Structural and biologic characterization of pegylated recombinant IFN-alpha2b.

  2001cited by this paper
• Estimating future hepatitis C morbidity, mortality, and costs in the United States.

  2000cited by this paper
• Identification of the major positional isomer of pegylated interferon alpha-2b.

  2000cited by this paper
• Rising incidence of hepatocellular carcinoma in the United States.

  1999cited by this paper
• Attachment of degradable poly(ethylene glycol) to proteins has the potential to increase therapeutic efficacy.

  1998cited by this paper
• A highly sensitive electrochemiluminescence immunoassay for interferon alfa-2b in human serum.

  1997cited by this paper
• Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity.

  1997cited by this paper
• An overview of the interferon system: signal transduction and mechanisms of action.

  1996cited by this paper
• Hepatitis C virus infection as a major risk factor for hepatocellular carcinoma.

  1996cited by this paper
• Biomedical and biotechnological applications of PEG- and PM-modified proteins.

  1995cited by this paper
• Principal component analysis and exploratory factor analysis

  1992cited by this paper
• The uses and properties of PEG-linked proteins.

  1992cited by this paper

• Advancing Viral Defense: Unravelling the Potential of Host-Directed Antivirals Against SARS-CoV-2

  2025cites this paper
• Polyethylene glycol-mediated functionalization of nanodelivery systems for improving their pharmacokinetic profile and anticancer efficacy

  2024cites this paper
• Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B

  2019cites this paper
• Postoperative low hepatitis C virus load predicts long‐term outcomes after hepatectomy for hepatocellular carcinoma

  2018cites this paper
• A Bayesian Approach for Population Pharmacokinetic Modeling of Pegylated Interferon α-2a in Hepatitis C Patients

  2017cites this paper
• Pulmonary sarcoidosis in the context of a telaprevir-based triple therapy for hepatitis C.

  2016cites this paper
• Pulmonary sarcoidosis in the context of a telaprevir-based triple therapy for hepatitis C.

  2016cites this paper
• IFN‐α promotes rapid human Treg contraction and late Th1‐like Treg decrease

  2016cites this paper
• Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa‐2a in hepatitis C null responders

  2015cites this paper
• PharmGKB summary: peginterferon-&agr; pathway

  2015cites this paper
• Down-regulation of suppressor of cytokine signaling 3 by miR-122 enhances interferon-mediated suppression of hepatitis B virus.

  2015cites this paper
• Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat

  2015cites this paper
• Impact of Diseases, Comorbidity, and Target Physiology on ADME, PK, and PK/PD of Therapeutic Biologics

  2015cites this paper
• Pegylated Interferon Pharmacokinetics and Self-Reported Depressive Symptoms During Antiviral Treatment for Chronic Hepatitis C

  2014cites this paper
• Improved Sustained Virological Response Following Treatment with Pegylated-Interferon Alpha-2b Compared with Alpha-2a, Both with Ribavirin, for Chronic Hepatitis C Infection with Genotypes 2 and 3

  2014cites this paper
• Differential Antiviral Effects of Pegylated Interferon-α2a and Pegylated Interferon-α2b in Chronic Hepatitis C

  2014cites this paper
• Comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis C: a retrospective study using the Japanese Interferon Database

  2014cites this paper
• Pegylated IFN-α regulates hepatic gene expression through transient Jak/STAT activation.

  2014cites this paper
• Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C.

  2014cites this paper
• Optimizing treatment for HCV genotype 4: PEG‐IFN alfa 2a vs. PEG‐IFN alfa 2b; the debate continues

  2014cites this paper
• Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.

  2013cites this paper
• Meta‐analysis: pegylated interferon α‐2a achieves higher early virological responses than α‐2b in chronic hepatitis C

  2013cites this paper
• Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C

  2013cites this paper
• Pegylated Interferon-a2a and Ribavirin versus Pegylated Interferon-a2b and Ribavirin in Chronic Hepatitis C

  2013cites this paper
• Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population

  2013cites this paper
• Pegylated Interferon-α2a and Ribavirin versus Pegylated Interferon-α2b and Ribavirin in Chronic Hepatitis C

  2013cites this paper
• Equal efficacy between the two types of peginterferon on HCV: a matter of relapse?

  2013cites this paper
• Antiviral activity of the interferon α family: biological and pharmacological aspects of the treatment of chronic hepatitis C

  2013cites this paper
• Cost-Effectiveness Analysis of Adding Low Dose Ribavirin to Peginterferon Alfa-2a for Treatment of Chronic Hepatitis C Infected Thalassemia Major Patients in Iran

  2013cites this paper
• Efficacy and Tolerability of Peginterferon α-2a and Peginterferon α-2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials

  2013cites this paper
• Treatment of Hepatitis C: How Will We Use Viral Kinetics, Response-Guided Therapy?

  2013cites this paper
• Treatment for Hepatitis C Virus Infection in Adults

  2012cites this paper
• Measuring HCV RNA and Assessing Virologic Response

  2012cites this paper
• Early and Sustained Virological Response in Non-Responders with Chronic Hepatitis C

  2012cites this paper
• Lymphatic Transport and Catabolism of Therapeutic Proteins Following Subcutaneous Administration to Rats and Dogs

  2012cites this paper
• Current status and future directions in the management of chronic hepatitis C

  2012cites this paper
• Pegylated Interferons for the Treatment of Chronic Hepatitis C

  2012cites this paper
• Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles

  2012cites this paper
• Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C

  2012cites this paper
• Lymphatic Transport and Catabolism of Therapeutic Proteins after Subcutaneous Administration to Rats and Dogs

  2012cites this paper
• Peginterferon-α-2a (40 kD) Plus Ribavirin

  2012cites this paper
• Interleukin-28B Genetic Variants and Peripheral Blood Interferon Receptor 2

  2012cites this paper
• Peptide and protein delivery

  2011cites this paper
• Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin.

  2011cites this paper
• The Treatment Response of Chronically Hepatitis C Virus-Infected Patients Depends on Interferon Concentration but Not on Interferon Gene Expression in Peripheral Blood Mononuclear Cells

  2011cites this paper
• Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma

  2011cites this paper
• Role of the nurse practitioner in the management of patients with chronic hepatitis C

  2011cites this paper
• Peginterferon and ribavirin treatment for hepatitis C virus infection.

  2011cites this paper
• Targeting of Toll-like receptors: a decade of progress in combating infectious diseases.

  2011cites this paper
• Genotype 1: Standard Treatment

  2011cites this paper
• Peptide and Protein Bioconjugation: A Useful Tool to Improve the Biological Performance of Biotech Drugs

  2011cites this paper
• Early viral kinetics: a novel guide for optimal dosing frequency of pegylated interferon-α-2a in HIV/HCV-coinfected patients

  2011cites this paper
• Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon a-2b for advanced hepatocellular carcinoma

  2011cites this paper
• Current treatment of choice for chronic hepatitis C infection

  2011cites this paper
• Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C

  2010cites this paper
• A perspective on modelling hepatitis C virus infection

  2010cites this paper
• New antiviral therapies for chronic hepatitis C

  2010cites this paper
• Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)

  2010cites this paper
• CLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT Randomized Study of Peginterferon-2a Plus Ribavirin vs Peginterferon-2b Plus Ribavirin in Chronic Hepatitis C

  2010cites this paper
• Chronic hepatitis C treatment in näive patients.

  2010cites this paper
• The Comparative Efficacy and Safety of Peginterferon Alpha-2a vs. 2b for the Treatment of Chronic HCV Infection: A Meta-Analysis

  2010cites this paper
• The Comparative Efficacy and Safety of Peginterferon Alpha-2 a vs . 2 b for the Treatment of Chronic HCV Infection : A Meta-Analysis

  2010cites this paper
• Outcome and Early Viral Dynamics with Viral Mutation in PEG-IFN/RBV Therapy for Chronic Hepatitis in Patients with High Viral Loads of Serum HCV RNA Genotype 1b

  2010cites this paper
• Type of Pegylated Interferon Matters: Another Milestone in the Treatment of Hepatitis C Virus Infection

  2010cites this paper
• A meta-analysis that compares the use of either peginterferon-α2a or peginterferon-α2b plus ribavirin for HCV infection

  2010cites this paper
• Peginterferon alpha‐2a is associated with higher sustained virological response than peginterferon alfa‐2b in chronic hepatitis C: Systematic review of randomized trials

  2010cites this paper
• Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis. A retrospective study in 507 patients.

  2010cites this paper
• A unique subset of Peyer's patches express lysozyme.

  2010cites this paper
• Efficacy and Tolerability of Pegylated Interferon-α2a plus Ribavirin versus Pegylated Interferon-α2b plus Ribavirin in Treatment-Naive Chronic Hepatitis C Patients

  2010cites this paper
• Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.

  2010cites this paper
• A case of severe thrombocytopenia in a patient with chronic hepatitis C caused by a single administration of pegylated interferon α 2a subsequent to 48 weeks of pegylated interferon α 2b plus ribavirin therapy.

  2010cites this paper
• Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C.

  2010cites this paper
• Do differences in pegylation of interferon alfa matter?

  2010cites this paper
• Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.

  2010cites this paper
• A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.

  2010cites this paper
• Hepatitis C therapy—the future looks bright

  2009cites this paper
• HBV and HCV Therapy

  2009cites this paper
• [Cost-effectiveness of chronic hepatitis C treatment in Spain].

  2009cites this paper
• Peginterferon Treatment In Children: A Review Of Chronic Hepatitis B And Chronic Hepatitis C Treatment

  2009cites this paper
• Quantitative determination of pegylated consensus interferon in rhesus monkey serum using a competitive enzyme-linked immunosorbent assay

  2009cites this paper
• A review of current anti-HCV treatment regimens and possible future strategies

  2009cites this paper
• Randomized trial comparing pegylated interferon α‐2b versus pegylated interferon α‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients

  2009cites this paper
• Pharmacotherapy of chronic hepatitis C virus infection – the IDEAL trial: ‘2b or not 2b (= 2a), that is the question’

  2009cites this paper
• Evaluation of newly developed combination therapy of intra‐arterial 5‐fluorouracil and systemic pegylated interferon α‐2b for advanced hepatocellular carcinoma with portal venous invasion: preliminary results

  2009cites this paper
• Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS).

  2009cites this paper
• Comparison of biochemical safety between PEG-IFN alpha-2a and PEG-IFN alpha-2b.

  2009cites this paper
• Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices

  2009cites this paper
• Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics

  2009cites this paper
• Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin.

  2009cites this paper
• Coste-eficacia del tratamiento de la hepatitis C crónica en España

  2009cites this paper
• Pegylated IFN-α2a and ribavirin in the treatment of hepatitis C

  2009cites this paper
• Tratamiento e historia natural de la Hepatitis crónica C en pacientes coinfectados por VIH-1

  2009cites this paper
• Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection.

  2008cites this paper
• Pegylated α‐interferon‐2a plus ribavirin compared with pegylated α‐interferon‐2b plus ribavirin for initial treatment of chronic hepatitis C virus: Prospective, non‐randomized study

  2008cites this paper
• Peg-Interferon Alpha-2a versus Peg-Interferon Alpha-2b in Nonresponders with HCV Active Chronic Hepatitis: A Pilot Study

  2008cites this paper
• Compare trial: updated data.

  2008cites this paper
• [Is the type of pegylated interferon important for response to treatment in patients with chronic hepatitis C infection?].

  2008cites this paper
• Eight‐week oral administration of meloxicam, a non‐steroidal anti‐inflammatory drug, prevents dose reduction of pegylated interferon α‐2a in the treatment of chronic hepatitis C

  2008cites this paper
• Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials

  2008cites this paper
• Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.

  2008cites this paper